Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice

Alberto Borghetti; Andrea Giacomelli; Vanni Borghi; Arturo Ciccullo; Alex Dusina; Massimiliano Fabbiani; Stefano Rusconi; Maurizio Zazzi; Cristina Mussini; Simona Di Giambenedetto

doi:10.1093/ofid/ofab103

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice

Alberto Borghetti, Andrea Giacomelli, Vanni Borghi, Arturo Ciccullo, Alex Dusina, Massimiliano Fabbiani, Stefano Rusconi, Maurizio Zazzi, Cristina Mussini, Simona Di Giambenedetto

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Article › peer-review

Abstract

The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.

Original language	English
Article number	ofab103
Journal	Open Forum Infectious Diseases
Volume	8
Issue number	7
DOIs	https://doi.org/10.1093/ofid/ofab103
Publication status	Published - Jul 2021

Keywords

dolutegravir
HIV
lamivudine
maintenance therapy
resistance-associated mutations

ASJC Scopus subject areas

Oncology
Clinical Neurology

Access to Document

10.1093/ofid/ofab103

Fingerprint

Dive into the research topics of 'Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice'. Together they form a unique fingerprint.

Cite this

Borghetti, A., Giacomelli, A., Borghi, V., Ciccullo, A., Dusina, A., Fabbiani, M., Rusconi, S., Zazzi, M., Mussini, C., & Di Giambenedetto, S. (2021). Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice. Open Forum Infectious Diseases, 8(7), [ofab103]. https://doi.org/10.1093/ofid/ofab103

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice. / Borghetti, Alberto; Giacomelli, Andrea; Borghi, Vanni et al.

In: Open Forum Infectious Diseases, Vol. 8, No. 7, ofab103, 07.2021.

Research output: Contribution to journal › Article › peer-review

Borghetti, A, Giacomelli, A, Borghi, V, Ciccullo, A, Dusina, A, Fabbiani, M, Rusconi, S, Zazzi, M, Mussini, C & Di Giambenedetto, S 2021, 'Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice', Open Forum Infectious Diseases, vol. 8, no. 7, ofab103. https://doi.org/10.1093/ofid/ofab103

Borghetti A, Giacomelli A, Borghi V, Ciccullo A, Dusina A, Fabbiani M et al. Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice. Open Forum Infectious Diseases. 2021 Jul;8(7):ofab103. doi: 10.1093/ofid/ofab103

@article{34f5b2a44ecf4ee7a4952b4ef3234d37,

title = "Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice",

abstract = "The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.",

keywords = "dolutegravir, HIV, lamivudine, maintenance therapy, resistance-associated mutations",

author = "Alberto Borghetti and Andrea Giacomelli and Vanni Borghi and Arturo Ciccullo and Alex Dusina and Massimiliano Fabbiani and Stefano Rusconi and Maurizio Zazzi and Cristina Mussini and {Di Giambenedetto}, Simona",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2021",

month = jul,

doi = "10.1093/ofid/ofab103",

language = "English",

volume = "8",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice

AU - Borghetti, Alberto

AU - Giacomelli, Andrea

AU - Borghi, Vanni

AU - Ciccullo, Arturo

AU - Dusina, Alex

AU - Fabbiani, Massimiliano

AU - Rusconi, Stefano

AU - Zazzi, Maurizio

AU - Mussini, Cristina

AU - Di Giambenedetto, Simona

PY - 2021/7

Y1 - 2021/7

N2 - The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.

AB - The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.

KW - dolutegravir

KW - HIV

KW - lamivudine

KW - maintenance therapy

KW - resistance-associated mutations

UR - http://www.scopus.com/inward/record.url?scp=85112481662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112481662&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofab103

DO - 10.1093/ofid/ofab103

M3 - Article

AN - SCOPUS:85112481662

SN - 2328-8957

VL - 8

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 7

M1 - ofab103

ER -

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this